JAMA Network
About The Study: In this cohort study of patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) use was associated with body mass index (BMI) -dependent cardiovascular benefits and consistent kidney protection, suggesting the importance of BMI stratification in guiding treatment decisions.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
